A company-sponsored clinical study of off-the-shelf K-NK003 cells in patients with relapsed/refractory acute myeloid leukemia (R/R AML)
Latest Information Update: 28 Feb 2020
At a glance
- Drugs K NK003 (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Kiadis Pharma
Most Recent Events
- 28 Feb 2020 New trial record
- 26 Feb 2020 According to an Kiadis Pharma media release, the Ohio State University and the company plan to work together to initiate a company sponsored trial with off-the-shelf K-NK003 cells expanded with particle production platform (PM21) in patients with relapsed/refractory acute myeloid leukemia later in 2020.